LINC01413: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01413

NCBI ID: G101928611

LINC01413

Other Name(s): long intergenic non-protein coding RNA 1413 | Long intergenic non-protein coding RNA 1413

LINC01413: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01413 is a long non-coding RNA (lncRNA) that has been identified in various cellular processes, including cell adhesion, migration, and tissue repair. Its unique feature is its ability to interact with several protein partners, which has led to its potential involvement in various biological processes. LINC01413 has also been shown to play a role in cancer progression and has been identified as a potential drug target or biomarker. In this article, we will explore the potential role of LINC01413 as a drug target or biomarker.

Potential Drug Target

LINC01413 has been shown to interact with several protein partners, including the protein known as PD-L1. PD-L1 is a transmembrane protein that is involved in immune regulation, and its dysfunction has been implicated in various diseases, including cancer. LINC01413 has been shown to regulate the activity of PD-L1, which could imply that it has potential as a drug target.

One of the potential benefits of targeting PD-L1 with LINC01413 is its potential to inhibit its functions in cancer cells. PD-L1 has been shown to promote the survival and proliferation of various cancer cell types, including cancer cells. By inhibiting PD-L1's effects, LINC01413 could potentially lead to the growth and spread of cancer cells.

Another potential benefit of targeting PD-L1 with LINC01413 is its potential to improve the effectiveness of current cancer treatments. PD-L1 has been shown to reduce the effectiveness of certain cancer treatments, including immunotherapy. By targeting PD-L1 with LINC01413, researchers could potentially develop new cancer treatments that are more effective against PD-L1-positive cancer cells.

Potential Biomarker

LINC01413 has also been shown to play a role in the development and progression of various diseases, including cancer. By regulating the activity of PD-L1, LINC01413 could potentially be used as a biomarker for cancer diagnosis and treatment. For example, LINC01413 levels could be used as a marker for the efficacy of cancer treatments.

In addition, LINC01413 has also been shown to play a role in tissue repair and regeneration. Its unique ability to interact with multiple protein partners has led to its potential involvement in various cellular processes, including tissue repair and regeneration. By targeting LINC01413 with small molecules or antibodies, researchers could potentially develop new treatments for various diseases, including tissue repair and regeneration.

Conclusion

In conclusion, LINC01413 is a long non-coding RNA that has been shown to interact with several protein partners and has the potential to be a drug target or biomarker. Its unique ability to regulate the activity of PD-L1 and its potential involvement in various cellular processes make it an attractive target for researchers to explore. Further studies are needed to fully understand the potential of LINC01413 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1413

The "LINC01413 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01413 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets